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Summary
Objectives: Cardiac involvement is an important prognostic factor in patients with
sarcoidosis. We evaluated the usefulness of delayed enhancement MRI (DE-MRI) for
diagnosing cardiac sarcoidosis by comparing with nuclear imaging and studying the
correlation between DE area and left ventricular (LV) function.
Methods: Twelve patients (male:female 3:9) diagnosed as having sarcoidosis under-
went Gd-MRI, myocardial perfusion SPECT (Tl-201, Tc-99m sestamibi), Ga-67
scintigraphy, and/or F-18 FDG-PET.
Results: DE was observed in 5 patients, and was positive in 39 (39%) of 100 LV seg-
ments. The corresponding perfusion defects in myocardial perfusion SPECT were
undetectable in 14 (36%) segments. DE distributedmainly in mid- to epi-myocardium,
and the lack of perfusion defects in myocardial perfusion SPECT was more prominent
in less transmural DE segments. Two patients with diffuse DE and 1 case with focal DE
exhibited positive cardiac uptake in Ga-67 scintigraphy, and 2 other cases with focal
DE showed cardiac uptake in F-18 FDG-PET. In 7 patients without DE, there were no
signiﬁcant ﬁndings in nuclear imaging. Both LV end-diastolic and end-systolic volume
were positively and LV ejection fraction was negatively correlated with the extent of
∗ Corresponding author. Tel.: +81 53 435 2759; fax: +81 53 435 2796.
E-mail address: wbs01352@mail.wbs.ne.jp (F. Matoh).
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DE area. Four patients treated with corticosteroid showed improvement in nuclear
imaging and slight decreases in DE area but no recovery in LV function.
Conclusions: DE-MRI is useful to diagnose the cardiac involvement of sarcoidosis and
to evaluate cardiac function. It is likely that the distribution of DE in mid- to epi-
myocardium is the characteristic of cardiac sarcoidosis, and the larger DE area may
be correlated with poor LV function.
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All the 12 patients underwent electrocardiogram-
gated MRI. Imaging was performed on a 1.5 T
MR system (Signa Inﬁnity Twinspeed, GE Medical© 2008 Japanese Colleg
reserved.
Introduction
Sarcoidosis is a multi-system disorder of unknown
etiology. Although the organ most frequently
involved is lung, all parts of the body can be
affected. Cardiac involvement is symptomatic in
only 5% of patients with sarcoidosis, whereas
sudden death resulting from ventricular tachy-
arrhythmias or conduction block accounts for
30—65% of death caused by sarcoidosis. Actually,
the cardiac involvement is apparent at postmortem
in 20—50% of patients [1—4]. In Japan, more
patients have cardiac lesions compared with those
in the western countries, and 47—78% of patients
die of cardiac events [5,6]. It has been reported
that the early initiation of corticosteroid therapy
improves left ventricular function and prevents
malignant arrhythmias [7,8].
Endomyocardial biopsy may be essential to diag-
nose cardiac sarcoidosis. However, it is invasive
and sometimes false negative because of inhomo-
geneous myocardial invasion of sarcoidosis lesion.
Although Tl-201 and Ga-67 scintigraphy have been
used to detect cardiac involvement in patients with
sarcoidosis [9—11], both methods are relatively low
in spatial resolution. Recent studies have revealed
that F-18 FDG-PET may be useful for the detec-
tion of cardiac sarcoidosis [12,13]. However, this
method is performed only in limited facilities and
requires a large amount of cost.
Myocardial magnetic resonance imaging (MRI) is
non-invasive, does not expose the patient to ion-
izing radiation, and is excellent for spatial reso-
lution. Delayed enhancement (DE)-MRI has been
shown useful to detect small and focal myocardial
abnormality [14—16]. Several reports have shown
that the distribution of DE in cardiac sarcoidosis
may be different from that in myocardial infarc-
tion [17—25]. However, it is still unclear whether
DE-MRI is actually useful to detect cardiac sarcoido-
sis, whether the extent of DE is associated with
cardiac dysfunction, and whether DE disappears by
corticosteroid therapy.
This study was planned to compare the use-
fulness of DE-MRI for the detection of cardiac
sarcoidosis with other nuclear imaging modalities,
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o examine the relationship between the extent of
E and left ventricular function, and to evaluate
he effects of corticosteroid therapy.
atients and methods
atients
e studied 12 patients (3 men, 9 women;
8.7± 11.3 years old) with sarcoidosis who under-
ent cardiac DE-MRI from May 2003 to January
006. The diagnosis of sarcoidosis was provided
istologically or according to Proposal by the Spe-
iﬁc Diffuse Pulmonary Disease Research Group,
arcoidosis Division by the Japanese Ministry of
ealth and Welfare [26]. The patient character-
stics are shown in Table 1. Ten of 12 patients
ere diagnosed as sarcoidosis by eye lesions or
ilateral hilar lymphadenopathy (BHL), and 3
atients were by histology in scalene nodes (cases
and 5) or a gastrocnemial muscle (case 11).
he cardiac involvement of sarcoidosis was also
valuated according to the criteria of the Japanese
ociety of Sarcoidosis and other Granulomatous
isorders [27]. As shown in Table 1, 8, 10 and
patients also underwent myocardial perfusion
ingle-photon emission computed tomography
SPECT) (7 cases with Tl-201 and 1 case with Tc-
9m sestamibi), whole-body Ga-67 planar imaging,
nd F-18 FDG-PET, respectively. This study protocol
as in accordance with the Declaration of Helsinki
nd approved by the institutional review board
Hamamatsu University School of Medicine, Hama-
atsu, Japan), and all patients gave informed
onsent.
RI protocolystems, Waukesha, Wis) with a gradient system
erformance of maximum amplitude of 40mT/m
nd slew time of 150 T/m/s. An 8-element phased
rray cardiac coil was used in all studies. Typi-
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Table 1 Patient characteristics and ﬁndings in DE-MRI and nuclear imaging
Patient no. Sex Age
(years)
Symptom Extra-
cardiac
lesions
ECG
ﬁndings
DE pattern LVEF with
Cine MRI (%)
ACE (IU/L) SPECT Ga-67 F-18 FDG
DE(+)
1 F 67 Dyspnea SN RBBB, LAD,
abnormal Q
Diffuse 11 3.9 (+) (+) N.A.
2 F 55 Dyspnea BHL Abnormal Q Diffuse 22 14.9 (+) (+) N.A.
3 F 56 Blurred
vision
Eye, skin,
BHL
Normal Focal 66 15.8 (−) (−) (+)
4 M 64 Blurred
vision,
dyspnea
Eye Normal Focal 58 8.9 (−) (−) (+)
5 F 41 Palpitation Eye, lung,
BHL, SN
Normal Focal 41 17.1 (−)* (+) N.A.
DE(−)
6 F 65 Blurred
vision
Eye, BHL Negative T 67 8.7 N.A. N.A. N.A.
7 F 67 (−) Eye Normal 70 N.A. N.A. N.A. N.A.
8 M 41 (−) BHL Normal 64 16.7 (−) (−) N.A.
9 F 77 Blurred
vision
Eye Normal 75 35.1 (−) (−) N.A.
10 M 57 (−) Eye, BHL Normal 55 11.9 (−) (−) N.A.
11 F 67 (−) Muscle Normal 70 22.6 N.A. (−) (−)
12 F 47 (−) Lung, BHL,
CNS
Normal 63 23.0 N.A. (−) N.A.
ACE: angiotensin-converting enzyme, DE: delayed enhancement, SPECT: defects in thallium-201 or technesium-99m sestamibi* SPECT, Ga-67: uptake in gallium-67 scintigraphy, F-18
FDG: uptake in ﬂuorosis-18 ﬂuorodeoxy glucose PET, SN: scalene node, BHL: bilateral hilar lymphadenopathy, CNS; central nervous system, RBBB: right bundle branch block, LAD: left
axis deviation, N.A.: not available.
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ation (S.D.). The Wilcoxon rank-sum test for
unpaired data was used to examine differ-182
cally, 3 planes such as short axis, sagittal long axis
and 4-chamber view were obtained for 2D FIESTA
cine images and delayed myocardial enhancement
images. 2D FIESTA cine images were based on
the steady state free precession (SSFP) sequence
and delayed myocardial enhancement imaging was
based on the inversion recovery prepared fast gra-
dient echo (IR-FGRE) sequence. The 6—9 slices
were used to cover whole heart. The slice thick-
ness/gap was typically 10mm/0mm. The matrix
was 192× 192 for 2D FIESTA cine, and 256× 160
for IR-FGRE. The trigger delay for IR-FGRE was
300ms; however, for the patients with tachy-
cardia, system-dependent trigger delay time was
selected, which was shorter than 300ms. The read-
out data line for IR-FGRE was 160 each, where
24 data lines were acquired per segment. FOV
was 34 cm for both sequences. Sixteen data lines
were acquired per each segment, and 16 phases
were acquired for 2D FIESTA cine sequences. Short-
est TR and TE were selected; however, the values
were not exactly the same for each study, because
they were related to the orientation of scanning
plane and slice thickness. Sequence parameters
were (2D FIESTA and IR-FGRE, respectively), ﬂip
angle: 45◦ and 20◦; readout bandwidth: 125 kHz
and 31.25 kHz. Breath-hold cine MR images were
obtained in contiguous short-axis planes from the
apex to the base of the heart with the patient
in a resting state. After the 2D FIESTA cine
images were acquired, 0.2mmol/kg of contrast
material (Gd-DTPA-BMA, Daiichi Pharma., Tokyo)
was injected, and after a 15min delay, delayed
myocardial enhancement images were acquired.
Thus, optimum TIs for the IR-FSPGR were mea-
sured right before the DE, which were between
200ms and 240ms. This process in search of
optimum contrast was concluded within three min-
utes.
Nuclear imaging protocol
The myocardial perfusion SPECT was performed
using Tl-201 or Tc-99m sestamibi (MIBI). The SPECT
images were obtained with a triple-head gamma
camera (PRISM 3000, Picker International, USA)
and a dual-head gamma camera (Millennium VG,
GE Yokokawa Co., Japan) equipped with low
energy high-resolution collimators, respectively.
The detailed protocols for SPECT were described
elsewhere [28].Ga-67 scintigraphy was performed using 111 MBq
Ga-67 citrate and a large ﬁeld of view gamma
camera (Prism 2000, Picker International, USA or
Millennium VG, GE Yokokawa Co., Japan) with
medium-energy and general purpose collimator.
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wenty percent windows were placed symmetri-
ally around each of the three main photopeaks of
a-67 (93 keV, 184 keV and 300 keV). Whole body
mages (anterior and posterior view images) were
aken at a speed of 8—10 cm/min on 72 h after
njection.
F-18 FDG-PET was performed using a SHR
2000 PET scanner (Hamamatsu Photonics, K.K.,
amamatsu, Japan) [29]. The SHR 22000 scanner
ermits simultaneous acquisition of 63 trans-
erse planes of 3.6-mm thickness encompassing
23.0-cm axial ﬁeld of view. The patients
asted for at least 5 h were asked to lie supine
n the imaging bed of the PET camera with
oth arms extended out of the ﬁeld of view.
nitial transmission scanning of the region of
nterest (ROI) was performed for 15min with a
ermanium-68 ring source. Acquired data were
ater used for attenuation correction in image
econstruction. Serum glucose levels measured
efore each PET scanning session were normal
72—118mg/dl).
nalysis of MRI and nuclear images
wo experienced cardiovascular radiologists inter-
reted all initial and follow-up MRIs and nuclear
mages without knowledge of clinical ﬁndings.
eft ventricular end-diastolic volume (LVEDV),
nd-systolic volume (LVESV), and ejection frac-
ion (LVEF) were acquired from the 2D FIESTA
ine images in short axis view. Regional analy-
es of DE-MRI and Tl-201 or Tc-sestamibi SPECT
ere performed using the 20-segments model
30]. The segmental transmural distribution of
E was also determined visually as endo-, mid-,
nd epi-myocardium. To estimate DE quantita-
ively, the DE area was traced manually and the
ercentage against total LV area was calculated
%DEA). The intra- and inter-observer variability
or measurement of %DEA were acceptable (intra-
bserver: r = 0.91, p < 0.01, inter-observer: r = 0.84,
< 0.01).
tatistical analyses
ata were expressed as means± standard devi-nces between groups. Correlation between the
xtent of DE (%DEA) and LV function was
ssessed by Pearson’s correlation coefﬁcient (r).
ifferences were considered signiﬁcant when
< 0.05.
DE-MRI in cardiac sarcoidosis 183
F enh
m C) T
p rior
R
P
T
t
i
o
D
w
t
D
a
t
L
r
a
a
p
o
l
D
s
a
w
(
(
T
I
s
o
s
2
m
e
r
o
u
e
4
a
T
(
C
A
e
pigure 1 A representative case with diffuse type delayed
ainly distributed in mid- to epi-myocardium (arrows). (
erfusion defects only in anterior, antero-septal and infe
esults
atient characteristics
able 1 summarizes the clinical characteristics of
he patients and the ﬁndings in myocardial imag-
ng. The delayed myocardial enhancement (DE) was
bserved in 5 of 12 patients. In the 5 patients with
E, 4 cases complained of dyspnea or palpitation,
hereas there was no case who had cardiac symp-
oms in the 7 patients without DE. The pattern of
E in the 5 positive cases was clearly discriminated
s diffuse or focal enhancement. In focal type DE,
he area of DE was less than 50% in each slice of
V. In patients with diffuse type DE, case 1 showed
ight bundle branch block, left axis deviation and
bnormal Q waves in V5, V6 leads, and case 2 had
bnormal Q waves in I, II, aVF, V3—V6 leads. In
atients with focal type DE and in those without DE,
nly case 6 exhibited negative T waves in V3—V6
eads. Thus, none of the patients with focal type
E or without DE satisﬁed the criteria of cardiac
arcoidosis.
The high angiotensin-converting enzyme (ACE)ctivity was seen only in case 9. LVEF obtained
ith cine MRI were 39.6± 23.3% in patients with DE
n = 5) and 65.6± 2.8% (n = 6) in patients without DE
p < 0.05 by Wilcoxon rank-sum test).
p
m
i
(
aancement (DE). (A) Cine MRI. (B) DE-MRI. The area of DE
he corresponding image of Tl-201 SPECT exhibited focal
segments (arrows).
he pattern of DE
n 2 cases with diffuse type DE, the enhancement
pread to almost all slices of LV, and the values
f total %DEA were 18.4% and 35%. Fig. 1 demon-
trates a typical case of diffuse type DE (case
). Notably, the area of DE mainly distributed in
id- to epi-myocardium. The Tl-201 SPECT image
xhibited only focal perfusion defects in ante-
ior, antero-septal and inferior segments. On the
ther hand, in 3 cases with focal DE, the val-
es of %DEA were 6.7%, 6.8% and 16.3%. Fig. 2
xpresses a typical case of focal type DE (case
). The DE existed only in the mid-ventricle of
ntero-lateral segment of LV (B), whereas the
l-201 SPECT image showed no perfusion defect
C).
omparison with nuclear cardiac imaging
s shown in Table 1, 2 patients with diffuse type DE
xhibited defects in myocardial Tl-201 SPECT and
ositive cardiac uptake in Ga-67 scintigraphy. Three
atients with focal type DE showed no defects in
yocardial perfusion SPECT, but had cardiac uptake
n Ga-67 scintigraphy (case 5) or in F-18 FDG-PET
cases 3 and 4). In 7 patients without DE, avail-
ble cases showed no defects in myocardial Tl-201
184 F. Matoh et al.
Figure 2 A representative case with focal type DE. (A) Cine
ventricle of antero-lateral segment of LV (arrow). (C) The co
defect.
SPECT, no uptake in Ga-67 scintigraphy or in F-18
FDG-PET.
Fig. 3 demonstrates the numbers of segments
that showed DE and defects in myocardial perfu-
Figure 3 The numbers of segments which showed DE and
defects in Tl-201 SPECT (parentheses) in patients with
DE. Among the 100 LV segments in 5 patients, DE was
observed in 39 (39%) segments. The DE spread to all the
LV segments, and there was no tendency in the distribu-
tion of DE. The numbers in parentheses indicate those
with perfusion defect in myocardial perfusion SPECT (Tl-
201 or Tc-99m sestamibi). In 14 of the 39 DE segments
(36%), the corresponding perfusion defects SPECT were
undetectable.
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LMRI. (B) DE-MRI. The area of DE existed only in the mid-
rresponding image of Tl-201 SPECT showed no perfusion
ion SPECT (in parentheses) in 5 patients with DE.
y the regional analysis using 20 segments model
30], the total of 100 LV segments in the 5 patients
ere analyzed. Among the 100 LV segments, DE was
bserved in 39 (39%) segments. The DE spread to all
he LV segments, and there was no tendency in the
istribution of DE. In 14 of the 39 segments (36%),
he corresponding perfusion defects in myocardial
erfusion SPECT were undetectable. Fig. 4 shows
he relationship between intramural distribution
f DE (open columns) and perfusion defects in
yocardial perfusion SPECT (ﬁlled columns). It was
vident that DE distributed in endo-myocardium
o trans-mural myocardium, but mainly in mid- to
pi-myocardium. All the segments with transmu-
al DE showed the perfusion defects in myocardial
erfusion SPECT. The lack of perfusion defects in
yocardial perfusion SPECT was more prominent in
ess transmural DE segments.
elationship between %DEA and LV function
ig. 5 shows the relationship between the extent of
E (%DEA) and LV function. The values are derived
rom patients without DE (open circles), those with
ocal type DE (closed circles), and those with dif-
use type DE (closed triangles), respectively. Both
VEDV and LVESV were positively correlated with
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Figure 4 The relationship between intramural distribution of DE (open columns) and corresponding perfusion defects
in myocardial perfusion SPECT (ﬁlled columns). DE distributed in endo-myocardium to transmural myocardium, but
m of perfusion defects in myocardial perfusion SPECT was more
p al transmural distribution of DE was determined visually in
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such as Tl-201 and Ga-67 scintigraphy have also
been used to detect cardiac involvement in patients
with sarcoidosis [9—11]. In the present study, no
patients with DE were proven to have sarcoido-
Figure 5 Relationship between %DEA and LVEDV (A),
LVESV (B) and LVEF (C). The values are derived from
patients without DE (open circles), those with focal typeainly in mid- to epi-myocardium. Additionally, the lack
rominent in less transmural DE segments. The segment
E-MRI. Endo, Mid, Epi: Endo-, mid-, epi-myocardium.
DEA (r = 0.88, and r = 0.88, p < 0.01). Conversely,
VEF was negatively correlated with %DEA (r = 0.85,
< 0.01).
orticosteroid therapy and DE
n 4 patients (cases 1, 3, 4 and 5) with DE, the cor-
icosteroid therapy was applied for 2—12 months.
n a patient with diffuse type DE (case 1), the
ecrease in %DEA and the increase in LVEF were
mall (%DEA: 18.4—15.1%, LVEF: 11—20%), but both
he defects in myocardial Tl-201 imaging and car-
iac uptake in Ga-67 scintigraphy disappeared. In 3
atients with focal type DE (cases 3, 4 and 5), %DEA
lightly decreased in 2 cases (6.7—7.7%, 7.7—5.7%
nd 16.3—13.7%), but LVEF did not change (67—66%,
3—51% and 41—41%). However, the cardiac uptake
n F-18 FDG-PET or Ga-67 scintigraphy apparently
ecreased in these cases.
iscussion
n this study, 5 of 12 (42%) patients with sarcoido-
is showed DE in cardiac DE-MRI, and the pattern
f DE was clearly discriminated as diffuse or focal
nhancement. The DE area mainly distributed in
id- to epi-myocardium, and the %DEA was signiﬁ-
antly correlated with LV function. DE-MRI is, there-
ore, useful to diagnose the cardiac involvement of
arcoidosis and to evaluate cardiac function.
he usefulness of DE to diagnose cardiac
nvolvement of sarcoidosis
ndomyocardial biopsy has been the only available
ethod to diagnose cardiac involvement of sar-
oidosis [31,32]. Several nuclear imagingmodalities
DE (closed circles), and those with diffuse type DE (closed
triangles), respectively. Both LVEDV and LVESV were
positively correlated with %DEA (r = 0.88, and r = 0.88,
p < 0.01). Conversely, LVEF was negatively correlated with
%DEA (r = 0.85, p < 0.01).
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sis lesion by endomyocardial biopsy. The 2 patients
with diffuse type DE exhibited defects in myocar-
dial Tl-201 imaging and positive cardiac uptake in
Ga-67 scintigraphy. In the 3 patients with focal type
DE, there were no defects in myocardial perfusion
SPECT, but F-18 FDG-PET showed positive cardiac
uptake in 2 cases and Ga-67 scintigraphy was posi-
tive in 1 case. However, according to the criteria
proposed by the Japanese Society of Sarcoidosis
and other Granulomatous Disorders [27], none of
the patients with focal type DE were diagnosed as
cardiac sarcoidosis.
DE in MRI relies on the delivery of intravenous
gadolinium chelate to the myocardium, which is a
biologically inert tracer that freely distributes in
extra-cellular space but does not cross the intact
cell membrane. Due to a combination of increased
extra-cellular volume and slower washout kinetics,
there is a relative accumulation of gadolinium in
areas of damaged myocardium in the late washout
phase [33].
It has been reported that cardiac MRI shows
DE in patients with cardiac sarcoidosis [17—25].
Shimada et al. reported a case of cardiac sarcoido-
sis in which Tl-201 image was normal but DE-MRI
indicated focal type DE in LV [19]. Although sev-
eral reports have shown that the distribution of
DE in cardiac sarcoidosis is different from that
in myocardial infarction or hypertrophic cardiomy-
opathy [14,24,34], there are few detailed studies
examining the distribution of DE in LV, and com-
paring it with the ﬁndings in nuclear imaging. In
a few reports concerning the pattern of DE, both
focal and diffuse types of DE were demonstrated
[17—25]. Smedema et al. reported that cardiac MRI
revealed DE in 19 of 58 patients with sarcoido-
sis, mostly involving basal and lateral segments
[25]. They also indicated that Tl-201 scintigraphy
was normal in 8 of the 19 patients. Their ﬁndings
are similar to our results, but have not indicated
whether DE distributes in endo-myocardium or in
mid- to epi-myocardium. Tadamura et al. reported
that the transmural extent of DE was related to the
defect score in 201-Tl SPECT and to wall motion
abnormality [24]. In the present study, the area of
DE distributed mainly in mid- to epi-myocardium in
all the 5 cases.
In addition, the pattern of DE was clearly dis-
criminated as diffuse or focal enhancement. In
2 cases with diffuse type DE, the enhancement
spreads to almost all the slices of LV, and the values
of total %DEA were 18.4% and 35%. On the other
hand, in the 3 cases with focal type DE, the val-
ues of %DEA were 6.7%, 6.8% and 16.3%. The reason
for the speciﬁc distribution of DE is unknown, but
the distribution of DE was obviously discordant with
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oronary circulation. In lung, the peri-lymphatic
rogression of sarcoid lesions was reported [35].
n attention should be paid to estimate DE-MRI,
ince DE-MRI in hypertrophic cardiomyopathy some-
imes demonstrates similar distribution pattern of
E [16,34]. We conclude that DE-MRI may be excel-
ent to detect focal involvement of sarcoidosis in
hich the 12-lead ECG or other imaging modalities
howed no abnormal ﬁndings.
E and cardiac function
he extent of DE has been related to the impair-
ent of LV function in cases with ischemic and in
ypertrophic cardiomyopathy [16,34,36]. In those
eports, LVEDV and ESV obtained with MRI became
igher and EF was lower as the DE area increased. In
his study, the %DEA was well correlated with LVEDV,
SV and EF. It is therefore indicated that the extent
f DE in cardiac sarcoidosis may also be related to
he impairment of LV function, although the pattern
f DE was much different from that in ischemic car-
iomyopathy. Actually, the 2 cases with diffuse type
E had depressed LV function and exhibited ECG
bnormalities (bundle branch block and abnormal
waves), whereas other cases showed no or only
inor ECG changes.
orticosteroid therapy and DE
a-67 scintigraphy and F-18 FDG-PET reﬂect the
ctivity of inﬂammation and also the involvement
f epithelioid cell granuloma in cardiac tissue.
herefore, these methods have been used for the
valuation of the corticosteroid therapy [37—39].
n the other hand, Tl-201 and Tc-99m MIBI express
brosis andmyocardial degeneration. As mentioned
bove, DE is due to a combination of increased
xtra-cellular volume and slower washout kinetics
33]. Therefore, DE can occur not only in ﬁbrous
car tissue but also when the volume of Gd distribu-
ion increases. In this study, 4 patients underwent
orticosteroid therapy for several months. In 1 case
ith diffuse type DE, both the defects in myocardial
l-201 SPECT and cardiac uptake in Ga-67 scintig-
aphy disappeared. In the 3 patients with focal
ype DE, the cardiac uptake in Ga-67 scintigraphy
r F-18 FDG-PET apparently decreased. However,
n those cases, the decreases in %DEA were small
r lacking. Since LVEF recovered slightly in the 1
ase but did not recover in the other 3 cases,
E may indicate the myocardial damage more
peciﬁcally compared with nuclear imaging that
ay reﬂect inﬂammation. Since DE is caused by
relative accumulation of gadolinium in areas
f expanded extracelluar space [40,41], DE in
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ardiac sarcoidosis may mean a combination of
brosis and interstitial edema. In fact, there are
everal reports that used DE-MRI for the eval-
ation of the corticosteroid therapy in cardiac
arcoidosis [19—21,42]. Shimada et al. described
hat the decrease in DE area by corticosteroid
herapy may be due to reduction of the intersti-
ial edema [19]. More recently, Tadamura et al.
eported a case in which DE area decreased by
orticosteroid therapy, but the wall motion abnor-
alities did not improve as similar to our ﬁndings
42].
imitations
he ﬁrst limitation in this study was that the
iagnosis of sarcoidosis was provided mainly by
ye lesions or by BHL. No patients with DE were
roven to have sarcoidosis lesion by endomyocar-
ial biopsy. In the 5 cases with DE, there were
o stenotic lesions in coronary arteriography and
o history of hypertension, valvular heart diseases
nd familiar cardiomyopathies. The second limita-
ion was that the examination of nuclear imaging
as not performed in all patients. Neither myocar-
ial perfusion SPECT nor Ga-67 scintigraphy was
vailable in 2 cases without DE, and F-18 FDG-
ET was examined only in 3 cases. Although the
ack of full examination was due to clinical and
conomical problems of the patients, this limita-
ion prevented detailed comparison between MRI
nd nuclear imaging modalities. The third lim-
tation was that there was no drastic recovery
f LV function by corticosteroid therapy. In the
cases treated with corticosteroid therapy, the
light decrease in DE area was seen in 3 cases.
herefore, at the present state, we could not deter-
ine whether DE means reversible or irreversible
yocardial damage.
onclusion
E-MRI is useful to diagnose the cardiac involve-
ent of sarcoidosis lesion and to evaluate cardiac
unction in patients with sarcoidosis. The dis-
ribution of DE in mid- to epi-myocardium may
e the characteristics of cardiac sarcoidosis, and
he increased DE area was associated with poor
V function. Further investigations are neces-
ary to determine whether DE-MRI is more useful
han endomyocardial biopsy or nuclear imag-
ng modalities to diagnose cardiac sarcoidosis
nd to evaluate the efﬁcacy of corticosteroid
herapy.
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